Source-grounded facts extracted from Scienture Holdings, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Narasimhan Mani was appointed as Interim Chief Financial Officer at Scienture Holdings, Inc..
“the Company appointed Dr. Narasimhan Mani (age 51) to serve as the Company’s Interim Chief Financial Officer ("Interim CFO") effective as of May 26, 2026.”
Eric Sherb resigned as Chief Financial Officer at Scienture Holdings, Inc..
“On May 26, 2026, Eric Sherb, the Chief Financial Officer ("CFO") of Scienture Holdings, Inc. (the "Company"), formally resigned his position as CFO and advised the Company that his resignation was due to personal reasons and not a result of any dispute or disagreement with the Company, its management, or its board of directors.”
Scienture Holdings, Inc. reported the three months ended March 31, 2026 results: revenue approximately $56 thousand.
“business update and reported financial results for the three months ended March 31, 2026. Q1 2026 Financial Highlights Compared to Q1 2025: ● Revenue increased to approximately $56 thousand for the three months ended March 31, 2026, compared to approximately $10 thousand in the prior-year three-month period, representing an increase of approximately 449%”
Scienture Holdings, Inc. incurred loan of $3 million with Streeterville Capital, LLC at 5% per annum maturing eighteen months following the date of issuance.
“On April 27, 2026, Scienture Holdings, Inc. (the “ Company ”) entered into and closed on a note purchase agreement (the “ Purchase Agreement ”) with Streeterville Capital, LLC, (the “ Lender ”) providing for the issuance of two secured promissory notes: (i) a Secured Promissory Note A-1 in the original principal amount of $8.42 million (the “ A-1 Note ”) and (ii) a Secured Promissory Note B in the original principal amount of $3 million (the “ B Note ”). The A-1 Note carries an original issue discount of $400,000 and the Company agreed to pay $20,000 to the Lender to cover the Lender’s transaction costs. The B Note does not carry an original issuance discount. At closing, the Lender paid $8 million to the Company and deposited an additional $3 million into an account at Lakeside Bank owned by the Company’s newly formed wholly-owned subsidiary, SCNX Holdings, LLC, a Utah limited liability company (“ SCNX Sub ”), to be held pursuant to a Deposit Account Control Agreement entered into amo”
Scienture Holdings, Inc. incurred loan of $8.42 million with Streeterville Capital, LLC at 9% per annum maturing eighteen months following the date of issuance.
“On April 27, 2026, Scienture Holdings, Inc. (the “ Company ”) entered into and closed on a note purchase agreement (the “ Purchase Agreement ”) with Streeterville Capital, LLC, (the “ Lender ”) providing for the issuance of two secured promissory notes: (i) a Secured Promissory Note A-1 in the original principal amount of $8.42 million (the “ A-1 Note ”) and (ii) a Secured Promissory Note B in the original principal amount of $3 million (the “ B Note ”). The A-1 Note carries an original issue discount of $400,000 and the Company agreed to pay $20,000 to the Lender to cover the Lender’s transaction costs. The B Note does not carry an original issuance discount. At closing, the Lender paid $8 million to the Company and deposited an additional $3 million into an account at Lakeside Bank owned by the Company’s newly formed wholly-owned subsidiary, SCNX Holdings, LLC, a Utah limited liability company (“ SCNX Sub ”), to be held pursuant to a Deposit Account Control Agreement entered into amo”
Scienture Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“October 14, 2025, Scienture Holdings, Inc. (the “ Company ”) received a written notice from the Listing Qualifications department of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock, par value $0.00001 (“ Common Stock ”) had been below $1.00 per share for 30 consecutive business days (the “ Minimum Bid Price Requirement ”). According to that notice, the Company has 180 calendar days, or until April 13, 2026, to regain compliance with the Minimum Bid Price Requir”
Scienture Holdings, Inc. incurred senior notes of $3,911,111.11 with Streeterville Capital, LLC at nine percent (9%) per annum maturing seven months following the date of issuance.
“On October 14, 2025, the Company entered into and closed on a note purchase agreement (the “ Purchase Agreement ”) with Streeterville Capital, LLC, (the “ Lender ”), which provided for the issuance of a senior secured promissory note in the principal amount of $3,911,111.11 (the “ Note ”).”
Scienture Holdings, Inc.: Amended Section 2.8 of the Bylaws to change stockholder meeting quorum requirement from a majority to one-third of voting stock (effective 2025-10-01).
“On October 1, 2025, the board of directors of Scienture Holdings, Inc. (the “ Company ”) voted to amend Section 2.8 the Company’s Amended and Restated Bylaws (the “ Bylaws ”) to change the requirements for quorum at a meeting of the stockholders of the Company from a majority of voting stock to one-third of the voting stock (the “ Amendment ”).”
Scienture Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“May 19, 2025, Scienture Holdings, Inc. (the “Company”) received a written notice from the Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock, par value $0.0001 (“Common Stock”) had been below $1.00 per share for 30 consecutive business days (the “Minimum Bid Price Requirement”). According to that notice, the Company has 180 calendar days, or until November 17, 2025, to regain compliance with the Minimum Bid Price Requirement. To”
Dr. Shankar Hariharan was appointed as Executive Chairman and co-Chief Executive Officer at Scienture Holdings, Inc..
“The board of directors also appointed Dr. Mani to serve as a director on the Company’s board of directors to fill the vacancy created as a result of Mr. Ajjarapu’s resignation and appointed Dr. Hariharan to the position of Executive Chairman of the Company’s board of directors, each effective as of May 20, 2025.”
Dr. Narasimhan Mani was appointed as co-Chief Executive Officer, President and Director at Scienture Holdings, Inc..
“the Company’s board of directors appointed Dr. Narasimhan Mani, age 50, and Dr. Shankar Hariharan, age 68, to serve as co-Chief Executive Officers of the Company effective as of May 20, 2025.”
Prashant Patel resigned as President and Chief Operating Officer at Scienture Holdings, Inc..
“As part of the planned leadership transition, Prashant Patel also advised the Company that he was resigning from his position as the Company’s President and Chief Operating Officer, effective as of May 20, 2025.”
Suren Ajjarapu resigned as Chief Executive Officer and Chairman of the Board at Scienture Holdings, Inc..
“On May 16, 2025, as part of a planned leadership succession, Suren Ajjarapu advised the Company that he was resigning from his position as the Company’s Chief Executive Officer and Chairman of the Board effective immediately.”
Prashant Patel resigned as Interim Principal Financial/Accounting Officer at Scienture Holdings, Inc..
“Mr. Patel notified the Company’s Board of Directors of his intention to resign his position as Interim Principal Financial/Accounting Officer effective as of the Effective Date.”
Eric Sherb was appointed as Chief Financial Officer at Scienture Holdings, Inc..
“On March 13, 2025, the Board of Directors of Scienture Holdings, Inc. (the “Company”) appointed Eric Sherb to serve as the Company’s Chief Financial Officer effective as of March 13, 2025”
Prashant Patel resigned as director at Scienture Holdings, Inc..
“On January 15, 2025 and January 16, respectively, Narasimhan Mani and Prashant Patel each voluntarily resigned as directors of Scienture Holdings, Inc.”
Narasimhan Mani resigned as director at Scienture Holdings, Inc..
“On January 15, 2025 and January 16, respectively, Narasimhan Mani and Prashant Patel each voluntarily resigned as directors of Scienture Holdings, Inc.”
Scienture Holdings, Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).
“January 3, 2025, Scienture Holdings, Inc. (the “Company”) received a written notice from the Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5620(a), due to the Company not holding an annual meeting of stockholders in 2024 within one year of the Company’s 2023 fiscal year end. The Company has until February 18, 2025, which is 45 days from the date of the notice, to submit a plan to regain compliance and, if Nasdaq accepts the plan, it may grant up to 180 calendar days from the fiscal year end”
Scienture Holdings, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).
“January 3, 2025, Scienture Holdings, Inc. (the “Company”) received a written notice from the Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance w”
Scienture Holdings, Inc. completed an acquisition involving Scienture, Inc. (closed 2024-07-25).
“The parties consummated the Mergers on July 25, 2024.”
Narasimhan Mani was appointed as Director at Scienture Holdings, Inc..
“on July 25, 2024, the Company’s Board appointed Shankar Hariharan and Narasimhan Mani to the Board.”
Shankar Hariharan was appointed as Director at Scienture Holdings, Inc..
“on July 25, 2024, the Company’s Board appointed Shankar Hariharan and Narasimhan Mani to the Board.”
Narasimhan Mani resigned as Director at Scienture Holdings, Inc..
“On June 17, 2024, Narasimhan Mani voluntarily resigned as a director of the Company.”
Subbarao Jayanthi was appointed as Director at Scienture Holdings, Inc..
“On June 17, 2024, the board of directors (the “Board”) of TRxADE Health, Inc. (the “Company”) appointed Subbarao Jayanthi to the Board.”
Michael L. Peterson resigned as Director at Scienture Holdings, Inc..
“On May 30, 2024, Jeff Newell and Michael L. Peterson each voluntarily resigned as a directors of the Company.”
Jeff Newell resigned as Director at Scienture Holdings, Inc..
“On May 30, 2024, Jeff Newell and Michael L. Peterson each voluntarily resigned as a directors of the Company.”
Narasimhan Mani was appointed as Director at Scienture Holdings, Inc..
“On May 28, 2024, the Company’s board of directors (the “Board”) appointed Mayur Doshi and Narasimhan Mani to the Board.”
Mayur Doshi was appointed as Director at Scienture Holdings, Inc..
“On May 28, 2024, the Company’s board of directors (the “Board”) appointed Mayur Doshi and Narasimhan Mani to the Board.”
Scienture Holdings, Inc. completed a disposition involving Superlatus Foods Inc. for $1.00 (closed 2024-03-05).
“arch 5, 2024, the Company entered in a Stock Purchase Agreement (“SPA”) with Superlatus Foods Inc. (the “Buyer”). Pursuant to the SPA, the Company sold all of the issued and outstanding stock (the “Stock”) of Superlatus Inc., a Delaware”
Scienture Holdings, Inc. entered into Stock Purchase Agreement with Superlatus Foods Inc. valued at $1.00 (effective 2024-03-05).
“On March 5, 2024, the Company entered in a Stock Purchase Agreement (“SPA”) with Superlatus Foods Inc. (the “Buyer”). Pursuant to the SPA, the Company sold all of the issued and outstanding stock (the “Stock”) of Superlatus Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Superlatus”), to the Buyer. The purchase price for the Stock was $1.00”
Scienture Holdings, Inc. entered into Subscription Agreement with Lafayette Energy Corp. valued at up to $5.0 million (effective 2024-02-29).
“On February 29, 2024, the Company’s wholly owned subsidiary Trxade, Inc. entered into a Subscription Agreement (the “Subscription Agreement”) with Lafayette Energy Corp., a Delaware corporation (“Lafayette”). Pursuant to the Subscription Agreement, Trxade, Inc. will, in two equal tranches, invest a total of up to $5.0 million in Lafayette in exchange for up to 2,000,000 shares of Lafayette’s newly created Series A Convertible Preferred Stock”
Scienture Holdings, Inc. completed a disposition involving Micro Merchant Systems, Inc. for $22.5 million (closed 2024-02-16).
“continue to own its assets that are unrelated to the web-based market platform operated by Trxade, Inc. The purchase price under the Purchase Agreement to be paid at closing is $22.5 million, subject to customary adjustments for cash, indebtedness, working capital and transaction expenses. Subject to the terms and conditions of the Purchase Agreement, if, during the”
Scienture Holdings, Inc. entered into Purchase Agreement with Micro Merchant Systems, Inc. valued at $22.5 million (effective 2024-02-16).
“TRxADE HEALTH Inc. (the “Company”) together with Trxade, Inc., a wholly owned subsidiary of the Company, and Micro Merchant Systems, Inc. (“MMS”) entered into an asset purchase agreement on February 16, 2024 (the “Purchase Agreement”) under which MMS agreed to purchase for cash substantially all of the assets of Trxade, Inc.”
Scienture Holdings, Inc. amended Amended and Restated Agreement and Plan of Merger with Superlatus, Inc. valued at Company Equity Value adjusted to 12,500,000; Merger Consideration adjusted to 1,712,328 shares of co (effective 2024-01-08).
“As previously reported on a Current Report on Form 8-K filed on July 31, 2023 TRxADE HEALTH, Inc., a Delaware corporation (the “Company”), completed its acquisition of Superlatus, Inc., (“Superlatus”) and Foods Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”) in accordance with the terms and conditions of the Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which the Company acquired Superlatus by way of a merger of the Merger Sub with and into Superlatus, with Superlatus being a wholly owned subsidiary of the Company and the surviving entity in the merger (“Merger”). Superlatus was not able to meet the post-closing condition of acquiring Prestige Farms, Inc. and on January 8, 2024, the Company entered into an amendment agreement to the Merger Agreement with Superlatus and Merger Sub (the “Amendment”).”
Scienture Holdings, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“November 21, 2023, the Company received a notice (the “Notice”) from the Nasdaq Listing Qualifications Department (“Nasdaq”) indicating that the Company is not compliant with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires listed companies to timely file all required periodic reports with the SEC. The Notice will have no immediate effect on the listing or trading of the Company’s common stock, although there can be no assurances that further delays in the filing of the Form 10-Q will not have an impact on the listing”
Scienture Holdings, Inc. entered into Supplier Agreement with Rainforest Distribution Corp (effective 2023-10-09).
“On October 9, 2023 (the “Effective Date”), Superlatus PD Holding Company (“Superlatus”), a Delaware corporation and wholly owned subsidiary of Superlatus, Inc. (a wholly owned subsidiary of TRxADE HEALTH, Inc.), entered into a supplier agreement (the “Supplier Agreement”) with Rainforest Distribution Corp, a New York corporation (“Rainforest”).”
Scienture Holdings, Inc.: Filed Certificate of Designation establishing Series C Preferred Stock with 1,000 authorized shares, $1,000 stated value per share, including dividend, voting, liquidation, conversion, and redemption terms (effective 2023-10-04).
“On October 4, 2023 (the “ Filing Date ”), the Company filed the Certificate of Designation with the Secretary of State of the State of Delaware designating 1,000 shares out of the authorized but unissued shares of its preferred stock as Series C Preferred Stock with a stated value of $1,000 per share.”
Scienture Holdings, Inc. engaged CM3 Advisory as its auditor.
“ngagement of CM3 Advisory On September 14, 2023, the Company engaged CM3 Advisory (“CM3”) as its new independent registered public accounting firm of”
Scienture Holdings, Inc. dismissed MaloneBailey, LLP as its auditor.
“ismissal of MaloneBailey, LLP On September 14, 2023, TRxADE HEALTH, Inc. (the “Company” or “MEDS”) dismissed MaloneBailey, LLP (“MaloneBailey”) as its independent registered public accounting firm to audit the Company’s financial statements, to be effective immediately.”
Scienture Holdings, Inc. entered into Asset Purchase Agreement with Perfect Day, Inc. and The Urgent Company, Inc. valued at $1,250,000 (effective 2023-08-21).
“On August 21, 2023 (the "Effective Date"), Superlatus, Inc., a Delaware corporation and wholly owned subsidiary of TRxADE HEALTH, Inc. ("Superlatus"), entered into an Asset Purchase Agreement (the "Asset Purchase Agreement") with Perfect Day, Inc., a Delaware corporation ("PD") and The Urgent Company, Inc., a Delaware corporation ("TUC" and together with PD, collectively, "Sellers").”
Scienture Holdings, Inc. completed an acquisition involving Superlatus, Inc. for 136,441 shares of common stock of the Company, representing 19.9% of the total issued and outstanding common stock of the Company after the consummation of the (closed 2023-07-31).
“the surviving entity in the Merger. Under the terms of the A&R Merger Agreement, at the closing of the Merger (the “Closing”), shareholders of Superlatus received in aggregate 136,441 shares of common stock of the Company, representing 19.9% of the total issued and outstanding common stock of the Company after the consummation of the Merger and 306,855 shares”
Scienture Holdings, Inc. entered into Amended and Restated Agreement and Plan of Merger with Superlatus, Inc. valued at 136,441 shares of common stock ... and 306,855 shares of Company's Series B Preferred Stock (effective 2023-07-14).
“on July 14, 2023, TRxADE HEALTH, Inc., a Delaware corporation (the "Company" or "MEDS") entered into a certain Amended and Restated Agreement and Plan of Merger (the "A&R Merger Agreement") with Superlatus, Inc., a U.S.-based holding company of food products and distribution capabilities ("Superlatus") and Foods Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company ("Merger Sub").”
Scienture Holdings, Inc. entered into Amended and Restated Agreement and Plan of Merger with Superlatus, Inc. valued at 30,821,941 shares of Company stock at $7.30 per share, comprised of 136,441 shares of common stock ( (effective 2023-07-14).
“As previously disclosed, on June 30, 2023, TRxADE HEALTH, Inc., a Delaware corporation (the “Company” or “MEDS”), entered into an Agreement and Plan of Merger (the “Original Merger Agreement”) with Superlatus, Inc., a U.S.-based holding company of food products and distribution capabilities (“Superlatus”). On July 14, 2023, the Company and Superlatus entered into an Amended and Restated Agreement and Plan of Merger (the “A&R Merger Agreement”; the transactions contemplated thereby, the “Merger”), which amends the merger consideration payable to the shareholders of Superlatus and adds the issuance of non-transferrable rights to receive shares of common stock of the Company at no cost to the shareholders of the Company in connection with the Merger.”
Scienture Holdings, Inc. entered into Agreement and Plan of Merger with Superlatus Inc. (effective 2023-06-30).
“On June 30, 2023, TRxADE Health, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Superlatus Inc., a Delaware corporation (“Superlatus”), and Foods Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”).”
Scienture Holdings, Inc.: Filed Certificate of Designation for Series B Preferred Stock, setting forth terms including non-participating, no dividends, no liquidation preference, no voting rights, no redemption rights, and conversion upon stockholder approval into 100 shares of common stock each (effective 2023-06-26).
“On June 26, 2023, the Company filed a Certificate of Designation, Preferences, Rights and Limitations of the Series B Preferred Stock with the Secretary of State of the State of Delaware (the “Certificate of Designation”).”
Scienture Holdings, Inc. received a nasdaq deficiency notice notice regarding other (rules 5550(a)(4)).
“June 23, 2023, the Listing Qualifications department of The Nasdaq Stock Market LLC (the “Nasdaq”) notified the Company that the Company was not in compliance with Nasdaq’s listing rules (the “Listing Rules”) as set forth in Listing Rule 5550(a)(4) given the Company’s failure to maintain a sufficient number of publicly held shares (the “Notice”). Citing the Company’s Event Form submitted to Nasdaq on June 7, 2023, Nasdaq calculated the Company’s publicly held shares as approximately 310,057 (which amount excludes shares held by officers, directors, or beneficial owners of 10 percent or more)”
Scienture Holdings, Inc. amended Amendment to Acquisition Letter with Superlatus, Inc. valued at Amendment to correct the number of shares to be received by Superlatus shareholders upon closing of (effective 2023-06-23).
“On June 23, 2023, the Company and Superlatus entered into an amendment (the “Amendment to Acquisition Letter”) to the LOI to correct the number of shares to be received by Superlatus shareholders upon closing of the Merger.”
Scienture Holdings, Inc. entered into Binding Letter of Intent for Merger with Superlatus, Inc. valued at 3,839,176 shares of the Company, valued at $58.61 per share, comprised of common stock (19.99% of to (effective 2023-06-22).
“On June 22, 2023, TRxADE HEALTH, Inc. (the “Company”) entered into a binding letter of intent (“LOI”) for a merger (the “Merger”) with Superlatus, Inc., a U.S.-based holding company of food products and distribution capabilities (“Superlatus”).”
Scienture Holdings, Inc. entered into LOI with Superlatus, Inc. (effective 2023-06-22).
“On June 22, 2023, TRxADE HEALTH, INC. (the "Company") entered into a binding letter of intent ("LOI") for a merger (the "Merger") with Superlatus, Inc., a U.S.-based holding company of food products and distribution capabilities ("Superlatus").”
Scienture Holdings, Inc.: Stockholders authorized the Board to amend and restate Article V, Subsection 3 of the Second Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio ranging from one-for-ten to one-for-hundred, at the Board's discretion, by December 31, 2023.
“The stockholders of the Company authorized the Board of Directors of the Company in its sole and absolute discretion, and without further action of the stockholders, to file a Certificate of Amendment at the 2023 Annual Meeting, which amends and restates subsection 3 of Article V ( Reverse Stock Split of Outstanding Common Stock ) to effect a reverse split of the Company’s issued and outstanding common stock, par value $0.00001 per share, at a ratio to be determined by the Board, ranging from one-for-ten to one-for-one hundred”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.